Browsing by Author "Espino Espino, Alberto Antonio"

Now showing 1 - 8 of 8
  • Thumbnail Image
    Item
    Esofagitis eosinofílica : Diagnóstico y manejo
    (2020) Ballart, M. J.; Monrroy Bravo, Hugo Alfonso; Iruretagoyena B., Mirentxu; Parada Daza, Alejandra; Torres Montes, Paula Javiera; Espino Espino, Alberto Antonio
  • No Thumbnail Available
    Item
    Features of gastrointestinal amyloidosis reply
    (2021) Latorre Selvat, Gonzalo Ignacio; Vargas Domínguez, José Ignacio; Espino Espino, Alberto Antonio
  • Thumbnail Image
    Item
    High Helicobacter pylori Bacterial Load and Low Cytokine Expression Levels Are Associated with Nodular Gastropathy
    (2020) Mansilla-Vivar, R.; Serrano Honeyman, Carolina; Palma, C.; Vera, M.; Hernandez, C.; Pizarro Rojas, Margarita Alicia; Torres Montes, Paula Javiera; Harris D., Paul R.; Fuentes López, Eduardo; Riquelme Pérez, Arnoldo; Espino Espino, Alberto Antonio; Mansilla-Vivar, R.; Serrano Honeyman, Carolina; Palma, C.; Vera, M.; Hernandez, C.; Pizarro Rojas, Margarita Alicia; Torres, Javiera; Harris D., Paul R.; Fuentes López, Eduardo; Riquelme Pérez, Arnoldo; Espino Espino, Alberto Antonio
  • Thumbnail Image
    Item
    Management of Helicobacter pylori infection in Latin America : A Delphi technique-based consensus
    (2014) Rollan, Antonio; Arab Verdugo, Juan Pablo; Camargo, M. Constanza; Candia Balboa, Roberto; Harris D., Paul R.; Ferreccio Readi, Catterina; Rabkin, Charles S.; Gana Ansaldo, Juan Cristóbal; Cortés, Pablo; Herrero, Rolando; Durán, Luisa; García, Apolinaria; Toledo, Claudio; Espino Espino, Alberto Antonio; Lustig, Nicole; Sarfatis Feige, Alberto; Figueroa, Catalina; Torres, Javier; Riquelme Pérez, Arnoldo
  • Thumbnail Image
    Item
    Metástasis pancreática como debut de carcinoma papilar de tiroides : caso clínico y revisión del perfil clínico patológico y molecular
    (2020) Uslar, T.; Chahuán, J.; Olmos Borzone, Roberto Ignacio; Rodríguez Poblete, Carolina Elena; Zoroquiain Vélez, José Pablo; Solar González, Antonieta Alejandra; Espino Espino, Alberto Antonio; León Ramírez, Augusto; Fardella B., Carlos; Domínguez Ruiz-Tagle, José Miguel; Astudillo, R.
  • Thumbnail Image
    Item
    Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease
    (Elsevier España, 2011) Espino Espino, Alberto Antonio; Villagran Torres, Andrea Alejandra; Vollrath Reyes, Valeska Yolanda; Hanckes Mayo, Maria Paulina; Salas Ocaranza, Roberto Ignacio; Farah Samaan, Andrea Catherina; Solis, Nancy; Pizarro Rojas, Margarita Alicia; Escalona Perez, Alex Gamaliel; Boza Wilson, Camilo; Perez, Gustavo; Carrasco, Gonzalo; Padilla, Orlando; Francisco Miguel, Juan; Nervi Oddone, Flavio; Chavez Tapia, Norberto C.; Arab Verdugo, Juan Pablo; Alvarez Lobos, Manuel Marcelo; Arrese Jimenez, Marco Antonio; Riquelme Perez, Arnoldo Javier
    Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis. Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients. Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism. Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 +/- 4.82) compared to controls (14.26 +/- 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 +/- 4.35) compared to patients without liver fibrosis (10.61 +/- 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6). Conclusions. Morbidly obese patients had significantly Lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
  • Thumbnail Image
    Item
    Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial
    (2018) Monrroy Bravo, Hugo Alfonso; Vargas Domínguez, José Ignacio; Glasinovic, Esteban; Candia, Roberto; Azua, Emilio; Galvez, Camila; Rojas, Camila; Cabrera, Natalia; Vidaurre, Josefa; Alvarez, Natalia; Gonzalez, Jessica; Espino Espino, Alberto Antonio; González Donoso, Robinson; Parra-Blanco
  • Thumbnail Image
    Item
    Validez y confiabilidad de una escala de clasificación de limpieza gástrica en endoscopia digestiva alta en población chilena
    (2016) Mansilla V., Rodrigo; Uslar N., Thomas; Chahuán A., Javier; Latorre S., Gonzalo; Cruz N., Rodrigo; Cruz Urrutia, Ricardo Javier; Sirhan Nahum, Marisol; Espino Espino, Alberto Antonio; Honold G., Francisca; Huenur F., Julieth; Miranda B., Paula; Riquelme Pérez, Arnoldo